TABLE III.

Analyses for Infected Participants Only, Not Adjusted for Age

			HSP90 vs. β-Actin		LEDGF/p75 vs. β-Actin		P21 vs. β-Actin		APOBEC3G vs. β-Actin
Group	Total	No. (%)	Fold change	P-value	Fold change	P-value	Fold change	P-value	Fold change	P-value
Among infected	33
Non-viremic		15 (45.4)	Ref		Ref		Ref		Ref
Viremic		18 (54.6)	−1.48	0.002	−1.15	0.05	1.03	0.94	−1.71	0.34
Among treated	21
Not on raltegravir		17 (81.0)	Ref		Ref		Ref		Ref
Raltegravir		4 (19.0)	−1.39	0.19	−1.28	0.04	1.12	0.85	−3.54	0.16
Among non-raltegravir	17
Not on protease inhibitors		7 (41.2)	Ref		Ref		Ref		Ref
On protease inhibitors		10 (58.8)	−1.17	0.49	−1.14	0.21	−1.20	0.71	−3.87	0.07
Among untreated	9
Viral load 100–1,000		3 (33.3)	Ref		Ref		Ref		Ref
Viral load >1,000		6 (66.7)	1.00	1.00	−1.16	0.36	−2.07	0.36	−4.39	0.28

Note: The fold changes were obtained from the 2^−ΔΔCt method and the P-values were obtained from Wilcoxon rank-sum test. Ref, Reference group.